Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2016-11-15 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It explains the reason for the delay in filing the Form 10-Q quarterly report for the period ended September 30, 2016. The document does not contain the actual financial statements or substantive financial data of the 10-Q report but rather notifies the SEC and investors about the delay and the reasons behind it. According to the rules, such a notification is not the report itself but an announcement related to the report's filing status. Therefore, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for filings that do not fit other specific categories and includes officer certifications, attestations, and notifications of late filings.
2016-11-15 English
FORM 8-K
Call Transcript Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 21, 2016, reporting on a live conference call held on October 20, 2016. It specifically mentions furnishing the conference call script as Exhibit 99.1. The text states that the information is being furnished and not filed, and the main content is the conference call script. There are no financial statements or detailed financial data presented, only a script of the call. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document length is 3015 characters, which is consistent with a transcript or script rather than a full report. Therefore, the appropriate classification is CT with high confidence.
2016-10-21 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 13, 2016, reporting the appointment of a new CEO and the departure of a former CFO, including details of employment and separation agreements. The key section is Item 5.02, which covers departure and appointment of directors or certain officers. There is no financial data or earnings information, nor is this a full annual or quarterly report. The document is primarily an announcement of management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is 5167 characters, which is sufficient to contain substantive information about management changes rather than a brief announcement or certification. Hence, the classification is MANG with high confidence.
2016-10-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the filing includes a press release about an accelerated plan for clinical trial drug production. There are no financial statements or detailed financial data included, and the document is relatively short (2497 characters). It primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-10-11 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details changes related to the company's board of directors and compensation policies for non-employee directors. It includes information about director compensation, stock option grants, and committee payments. This fits the description of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board or senior management. The document is not a full annual report, earnings release, or other financial report, but rather a regulatory filing announcing board-related changes. The document length is 3557 characters, which is typical for an 8-K filing of this nature. Therefore, the correct classification is MANG with high confidence.
2016-09-28 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-09-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.